113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JMA-IIA00134 | 14/08/2013 | 05/08/2013 | Phase II study of nonsense readthrough compound NPC-14 (Arbekacin sulfate) to explore safety, tolerability, and efficacy in Duchenne muscular dystrophy patients (NORTH POLE DMD study) | Phase II study of nonsense readthrough compound NPC-14 (Arbekacin sulfate) to explore safety, tolerability, and efficacy in Duchenne muscular dystrophy patients (NORTH POLE DMD study) | Duchenne muscular dystrophy | Intervention type:DRUG. Intervention1:NPC-14, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP, intended dose regimen:Not applicable. Control intervention1:Placebo, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP, Intended dose regimen:Not applicable. | Yasuhiro Takeshima, MD, PhDHyogo College of Medicine Hospital, department of pediatrics | Not applicable | Completed | >=4 YEARS | No Limit | Male | 21 | Phase 2 | Japan |
| 2 | NCT01918384 (ClinicalTrials.gov) | August 2013 | 1/8/2013 | Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy | Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study) | Muscular Dystrophy, Duchenne | Drug: NPC-14;Drug: Placebo | Kobe University | Japan Medical Association;Nobelpharma | Active, not recruiting | 4 Years | N/A | Male | 21 | Phase 2 | Japan |